Becerra: Medicare premium increase re-evaluation after Biogen Aduhelm price cut

designer491/iStock via Getty Images

• HHS Secretary Xavier Becerra has ordered a re-evaluation of a planned Medicare premium increased spurred by Biogen's (BIIB +0.5%) Alzheimer's treatment Aduhelm (aducanumab) after the company cut the price in half, the Associated Press reports.
• "With the 50% price drop of Aduhelm on Jan. 1, there is a compelling basis ... to reexamine the previous recommendation," Becerra told the news service.
• In December, Biogen halved the price of Aduhelm to $28,200 per year for an average patient following pressure over its high price tag and questionable efficacy.
• AP says that the Part B premium is going up by ~$22 this year from $148.50 last year. Around $11 of that rise was due to the former $56K annual price of covering Aduhelm.
• Biogen presented at the J.P. Morgan Health Care conference this morning.

Comments

[22thoroughbred]

So I got my SSDI payment reduced for 1 product that Medicare doesn’t cover and now they might. Not how a co. does biz.